Literature DB >> 8437512

BQ-123, a peptidic endothelin ETA receptor antagonist, prevents the early cerebral vasospasm following subarachnoid hemorrhage after intracisternal but not intravenous injection.

M Clozel1, H Watanabe.   

Abstract

The aim of this study was to evaluate the role of endothelin and endothelin ETA receptor in the early cerebral vasoconstriction following subarachnoid hemorrhage (SAH) in the rat. SAH induced by injection of autologous blood in the cisterna magna reduced by 22 to 38% cerebral blood flow (CBF) measured with radioactive microspheres at 30, 60 and 120 min after SAH. The cyclic pentapeptide BQ-123, a selective antagonist of the ETA receptor, injected intravenously (3 mg/kg) had no effect on this decrease in CBF. However, intracisternal BQ-123 (10 nmol) completely prevented the decrease in CBF at 60 and 120 min after SAH. These results suggest that BQ-123 does not cross the blood-brain barrier, but demonstrate that endothelin acting on ETA receptor plays a role in the pathogenesis of cerebral vasoconstriction in this rat model of SAH.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8437512     DOI: 10.1016/0024-3205(93)90081-d

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  17 in total

1.  Role of endothelin-1 in human aneurysmal subarachnoid hemorrhage: associations with vasospasm and delayed cerebral ischemia.

Authors:  Bhavani P Thampatty; Paula R Sherwood; Matthew J Gallek; Elizabeth A Crago; Dianxu Ren; Allison J Hricik; Chien-Wen J Kuo; Megan M Klamerus; Sheila A Alexander; Catherine M Bender; Leslie A Hoffman; Michael B Horowitz; Amin B Kassam; Samuel M Poloyac
Journal:  Neurocrit Care       Date:  2011-08       Impact factor: 3.210

2.  Intraspinal application of endothelin results in focal ischemic injury of spinal gray matter and restricts the differentiation of engrafted neural stem cells.

Authors:  Richard L Benton; John P Woock; Evelyne Gozal; Michal Hetman; Scott R Whittemore
Journal:  Neurochem Res       Date:  2005 Jun-Jul       Impact factor: 3.996

Review 3.  The importance of early brain injury after subarachnoid hemorrhage.

Authors:  Fatima A Sehba; Jack Hou; Ryszard M Pluta; John H Zhang
Journal:  Prog Neurobiol       Date:  2012-03-10       Impact factor: 11.685

4.  Influence of different degrees of liver impairment on the pharmacokinetics of clazosentan.

Authors:  Shirin Bruderer; Victor Detishin; Nahum Tsvitbaum; Jasper Dingemanse
Journal:  Br J Clin Pharmacol       Date:  2011-01       Impact factor: 4.335

5.  Inhibition of endothelin-1 receptors improves impaired nitric oxide synthase-dependent dilation of cerebral arterioles in type-1 diabetic rats.

Authors:  Denise M Arrick; William G Mayhan
Journal:  Microcirculation       Date:  2010-08       Impact factor: 2.628

6.  Mechanisms of central endothelin-induced hypotension.

Authors:  A S Tadepalli; M A Hashim
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-07       Impact factor: 3.000

7.  ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro.

Authors:  J J Maguire; A P Davenport
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

8.  Protective effects of endothelin-1 on acute pancreatitis in rats.

Authors:  M Kogire; K Inoue; S Higashide; K Takaori; Y Echigo; Y J Gu; S Sumi; K Uchida; M Imamura
Journal:  Dig Dis Sci       Date:  1995-06       Impact factor: 3.199

9.  [D-Val22]big ET-1[16-38] inhibits endothelin-converting enzyme activity: a promising concept in the prevention of cerebral vasospasm.

Authors:  Michael Zimmermann; Carla Sabine Jung; Hartmut Vatter; Andreas Raabe; Volker Seifert
Journal:  Neurosurg Rev       Date:  2002-11-19       Impact factor: 3.042

Review 10.  Effect of endothelin receptor antagonists on clinically relevant outcomes after experimental subarachnoid hemorrhage: a systematic review and meta-analysis.

Authors:  Kamil G Laban; Mervyn D I Vergouwen; Rick M Dijkhuizen; Emily S Sena; Malcolm R Macleod; Gabriel J E Rinkel; H Bart van der Worp
Journal:  J Cereb Blood Flow Metab       Date:  2015-05-06       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.